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Abstract
The US Secretary of Health and Human Services recommended in February 2016 that 
mucopolysaccharidosis type 1 (MPS I) be added to the recommended uniform screening panel for 
state newborn screening programs. One of the key factors in this decision was the evidence 
suggesting that earlier treatment with hematopoietic cell transplantation (HCT) for the most severe 
form, Hurler syndrome (MPS IH), would lead to improved cognitive outcomes. Consistent 
evidence from peer-reviewed studies suggests that transplantation in the first year of life is 
associated with improved developmental quotient or intelligence quotient and continued cognitive 
growth, with earlier age of treatment associated with improved outcomes. However, available 
evidence suggests that cognitive functioning and attention can still lag behind unaffected age-
matched children, leading to the need for special education services. Verbal and nonverbal 
cognitive abilities outcomes may be affected differently by HCT. With the recent addition of MPS 
I to the recommended uniform screening panel, future work is needed to evaluate the impact of 
earlier, presymptomatic detection and treatment initiation and other supportive therapies on 
cognitive outcomes.
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INTRODUCTION
In February 2016, mucopolysaccharidosis type 1 (MPS I) was added to the recommended 
uniform screening panel (RUSP) for newborn screening by the US Secretary of Health and 
Human Services. This addition was based in part on a recommendation from the Advisory 
Committee on Heritable Disorders in Newborns and Children (hereafter, Advisory 
Committee), which noted that screening using dried bloodspots could effectively identify 
cases of the most severe phenotype in infancy and lead to long-term improved cognitive 
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outcomes.1 Although treatment of MPS I can be lifesaving, the evidence regarding the 
benefit of presymptomatic detection is not supportive of a difference in mortality. However, 
the evidence is supportive of early treatment leading to differences in cognitive outcome. 
The rationale for adding MPS I to newborn screening is therefore different from that for 
many other metabolic disorders on the RUSP.
To evaluate MPS I for the RUSP, the Advisory Committee first considered a systematic 
evidence review conducted by the Condition Review Workgroup that addressed the natural 
history of MPS I, the accuracy of availability of screening tests, and the benefits and harms 
of early detection and treatment.1 at systematic evidence review was restricted to English-
language articles published from 2003 through 2014, which included only one study2 that 
specifically addressed treatment and cognitive outcomes for the most severe form of MPS I. 
To further inform the Advisory Committee, the first author of our report (S.D.G.) prepared a 
narrative review of MPS I treatment and cognitive outcomes, which included studies 
published before and after the time window of the systematic evidence review. Our report 
provides a summary of the evidence that informed the Advisory Committee regarding the 
cognitive outcomes associated with MPS I and the impact of therapy on those outcomes.
MPS I overview
MPS I is an autosomal recessive lysosomal storage disorder resulting from deficiency of the 
enzyme α-L-iduronidase, affecting approximately 1 in 100,000 births.1 Most children with 
MPS I appear normal at birth and begin to show signs or symptoms later in infancy (e.g., 
changes in physical appearance, inguinal or umbilical hernias, and loss of speech or learning 
skills).3 Traditionally, MPS I is classified as one of three phenotypes, Hurler syndrome 
(OMIM 607014), Hurler-Scheie syndrome (OMIM 607015), or Scheie syndrome (OMIM 
60716). Hurler syndrome, also referred to as MPS IH or severe MPS I, is the predominant 
form and, when untreated, is associated with rapid and progressive multisystem disease with 
profound central nervous system involvement in the first 2 years of life and death before 10 
years of life. In contrast, Hurler-Scheie syndrome and Scheie syndrome, together referred to 
as attenuated MPS I (MPS IA), have later onset, slower progression, and typically little or no 
central nervous system involvement. Untreated, Hurler-Scheie syndrome is associated with 
death in the second or third decade of life. In contrast, most individuals with Scheie 
syndrome have a normal lifespan. Enzyme replacement therapy (ERT) with laronidase is 
available for MPS I. However, because laronidase does not penetrate the blood–brain barrier, 
hematopoietic cell transplantation (HCT) is recommended for MPS IH in addition to ERT.4 
Guidelines recommend HCT for patients with MPS IH who are younger than 30 months old 
and have an estimated developmental quotient (DQ) of at least 70. These restrictions are 
based on the expected benefits of HCT on long-term outcomes and overall posttransplant 
event-free survival, which is estimated to be 90%.5
Natural history of cognitive outcomes in MPS I
Untreated children with MPS IH develop progressive cognitive decline relative to age-
specific norms beginning at approximately 6 months of age,6 and the degree of cognitive 
impairment increases over time. Among a series of 15 untreated children with MPS IH, the 
median DQ decreased from an average of 80 (below average) prior to 2 years of age to 61 
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(well below average) after 2 years of age.7 After excluding two outliers, the correlation 
between DQ and age in years was −0.82. A more recent report of 22 untreated children, 
including the 15 previously described, found a mean IQ of 67 (well below average) at a 
mean age of 2.28 years.8 Across the population, the IQ decreased with increasing age, and 
all died in early childhood.
In general, natural history studies have not reported cognitive impairment among untreated 
children with MPS IA. However, treatment studies suggest that cognitive impairment might 
be an important feature of the condition.
Treatment and cognitive outcomes for MPS IH
Natural history studies show that untreated MPS I is associated with cognitive declines that 
result in cognitive skills that are well below average (i.e., mean DQ scores between 61 and 
67 points in two studies).7,8 Past research has shown that HCT prevents progressive 
deterioration in cognitive outcomes into the extremely low average range among children 
with MPS IH,9,10 although cognitive functioning remains below average for some children 
compared with same-aged peers. Regardless of statistical significance or comparisons with 
other groups, clinically meaningful cognitive improvement may be demonstrated with HCT 
treatment. Moderate effect sizes (≥0.50 standard deviation) or approximately seven 
standardized test points after HCT treatment (e.g., DQ scores between 68 and 74 points 
when compared to previous studies) are likely to yield meaningful benefit for the patient 
and/or family.11 Three studies published in the 1990s reported that after HCT, only 
approximately half had no deterioration or improved cognitive performance; the remaining 
had lower cognitive scores.12–14 More recently, Eisengart and colleagues15 reported that 
among 10 patients who received HCT but no ERT, at a mean age of 17 months the mean 
overall cognitive composite standard score was 91 (average) before transplantation and 
declined during the 2-year follow-up period to a mean of 71 points (below average). 
Children who received HCT had a significantly higher rate of decline in the visual reception 
domain—a subscale measure of nonverbal learning abilities—than children who received 
both HCT and ERT.
Aldenhoven and colleagues16 reported data for 217 patients with MPS IH who underwent 
successful engrafting following HCT at 10 centers worldwide between 1985 and 2011. 
Overall, patients underwent transplantation at a median age of 16 months, with last follow-
up at a median of 110 months. The prevalence of below-average cognitive functioning (DQ 
or IQ <85) in this sample increased from 43% prior to HCT to 73% at last follow-up. The 
prevalence of intellectual disability (DQ or IQ <70) increased from 17 to 45%. Male sex, 
lower baseline DQ or IQ, older age at HCT, use of total body irradiation, and older age at 
evaluation were each associated with poorer cognitive outcomes after HCT.
Shapiro and colleagues8 reported cross-sectional assessments for 60 patients with MPS IH 
treated at five US and Canadian centers. Fourteen children assessed pre-HCT (≤ age 24 
months), had a mean age of treatment of 7.5 months, and a mean pre-HCT IQ score of 91 
(average range). Among 46 children and young adults assessed between 2 – 25 years of age, 
mean age of treatment was 11.4 to 12.6 months, with IQ scores averaging 76 (below average 
range). Of the 14 children in the pre-HCT sample, 7% had intellectual disability (IQ <70); 
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37–42% of the 46 children in the older age groups who had undergone transplantation years 
earlier had intellectual disability. Among children treated with HCT, there was a difference 
of 9 points between the children’s verbal IQ scores before and after HCT and a difference of 
14 points between the children’s nonverbal IQ scores before and after HCT. The strongest 
predictors of cognitive outcome were genotype and age at HCT. More than 90% of children 
required special education or therapy services after HCT. The authors concluded that HCT is 
associated with stabilization of cognitive ability rather than continued progressive decline in 
MPS IH patients, even though below-average functioning remains prominent.
Two smaller studies reported more positive post-HCT cognitive outcomes. Souillet17 
followed 15 children with MPS IH who underwent transplantation at ages 14–51 months for 
at least 36 months after HCT. All children experienced progress after HCT but later showed 
decreases in age-equivalent cognitive scores, followed by apparent stabilization. None of the 
subjects had intellectual disability (IQ <70). However, most had reported problems with 
concentration, memory, and language, and only one in five children older than age 12 years 
did not require special services at school. Another study18 similarly reported motor and 
language delays in six children with MPS IH who underwent transplantation before 24 
months, followed by continued cognitive and/or language delays in four of six children 24 
months after transplantation, and then stabilization of cognitive development before reaching 
school age.
Age of treatment and cognitive outcomes for MPS IH
One of the most consistent findings in the recent MPS I literature is that younger age at HCT 
treatment is associated with improved cognitive outcomes. These studies are reviewed here 
and summarized in Table 1. A 1995 report by Shapiro and colleagues7 analyzed data for 21 
children with MPS IH without baseline intellectual disability (DQ >70) and followed at least 
12 months after transplantation. The mean decrease in standard scores was 4 points per year 
for children who underwent transplantation before 24 months and 7 points per year for 
children who underwent transplantation between 24 and 36 months of age. Mean scores 
decreased by 9 points, from 88 (average) to 79 (below average), for the early-transplant 
group (mean, 28 months of follow-up) and by 24 points, from 87 (average) to 63 (well below 
average), for the late-transplant group (mean, 50 months of follow-up). The percentages with 
intellectual disability (standard score <70) were 29% (four of 14) for the group who 
underwent transplantation before age 24 months and 57% (four of seven children) for the 
group transplanted between ages 24 and 36 months. The percentages with severe intellectual 
disability (standard score <50) were 7% (one of 14) for the group who underwent 
transplantation before age 24 months and 57% (four of seven) for the group transplanted 
between ages 24 and 36 months.
Peters et al.14 also reported cognitive outcomes stratified by age at transplantation for those 
younger than 24 months and those older than 24 months. Of 14 children who underwent 
transplantation when they were younger than 24 months, 9 were reported to have had 
“relatively normal” development, meaning that mental age increased over time by at least 
50% of the chronological age, and 5 experienced slower than expected development. Of 12 
children who were transplanted after age 24 months, three had “relatively normal” 
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development, four had slower than expected development, and five children plateaued in 
development or failed to progress further. The mean difference in cognitive growth 
trajectories between children who underwent transplantation before and after age 24 months 
was significant and indicated that children transplanted before age 24 months showed more 
cognitive progression than children transplanted after age 24 months. Moreover, children 
who underwent transplantation before age 24 months were less likely to plateau or show a 
leveling off of cognitive skills than children transplanted after 24 months.
Wraith and colleagues19 reported cognitive growth outcomes for 20 children between 6 and 
61 months of age with MPS I who were enrolled in a year-long open-label trial of ERT 
without HCT. The fastest growth in cognitive skills occurred among the eight children with 
MPS IH who were younger than 30 months and all four of the children with MPS IA 
regardless of age. Children with MPS IH who were older than 30 months showed a 
developmental plateau in cognitive skills. The authors noted that longer follow-up is needed 
to determine whether developmental gains made by children with MPS IH who were 
younger than 30 months at the time of enrollment are sustained.
Poe and colleagues2 enrolled 31 patients who underwent transplantation at two US 
institutions between 1997 and 2013. DQ scores were calculated before HCT and at least two 
times after HCT, with a median of seven subsequent evaluations. A longitudinal regression 
analysis was used to evaluate the relationship between age at transplantation and cognitive 
outcome. Younger age at transplantation was associated with better long-term cognitive 
outcomes (P < 0.001), with each month of transplantation delay associated with a greater 
deficit in long-term outcomes. Moreover, children who underwent transplantation at younger 
ages had significantly better subscale scores for expressive and receptive language functions 
than those transplanted at later ages (P = 0.01 and 0.004, respectively). The authors did not 
report nonverbal cognitive skills independent of language function.
The study investigators also reported individual and model-generated average trajectories 
stratified by age at transplantation.2 Results showed that individual children in the late-
transplant group were more likely to perform at the lowest developmental levels and were 
more likely to plateau in development, although there was no evidence of further 
deterioration after a posttransplantation decline. In contrast, the two groups who underwent 
transplantation before 18 months of age showed development within the normal range. The 
earliest transplant group (ages 2–8 months) showed normal cognitive, expressive language, 
and receptive language development, with the average trajectory at or near the 50th 
percentile in normal populations. In a fixed-effects model, the children who underwent 
transplantation at 2–8 months had significantly better cognitive function than those 
transplanted after 8 months (P = 0.001). The group transplanted between ages 9 and 17 
months performed, on average, below the 50th percentile but within 2 standard deviations of 
the normal population distribution in all developmental domains. The group who underwent 
transplantation after 18 months performed, on average, more than 2 standard deviations 
below the mean in all developmental domains.
Aldenhoven and colleagues16 charted average developmental trajectories for 217 children 
who underwent transplantation at 10 centers in Europe and the United States from 1985 
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through 2011 and were stratified separately by pre-HCT DQ and age at HCT. ose 
transplanted before the median age of 16 months had higher developmental ages throughout 
follow-up relative to those transplanted after 16 months. The regression analysis indicated 
that later transplantation was associated with an 8.4-point reduction in cognitive scores at 
last follow-up. Baseline DQ <85 was associated with an 8.6-point reduction in cognitive 
scores at last follow-up. The authors concluded that early diagnosis through newborn 
screening is likely to result in better cognitive outcomes for children with MPS IH in two 
ways. First, younger age of HCT directly predicts better cognitive test scores. Second, 
younger age at HCT is associated with higher baseline DQ at the time of HCT, which is also 
an important predictor of neurodevelopment in children with MPS IH.
Shapiro and colleagues8 analyzed cross-sectional data for 60 patients with MPS IH, of 
whom 14 were administered ERT prior to HCT and 46 were assessed post-HCT. Of those 
assessed post-HCT, 19 were assessed at ages 24–71 months and 27 after 71 months. A 
regression analysis found that the most powerful predictor of IQ scores was genotype, with 
nonsevere mutations associated with scores higher by approximately 20 points. Age at 
treatment was also significant, with an average 8-point decrease in cognitive scores for each 
year treatment was delayed. The authors also noted that patients who underwent a second 
HCT had lower IQ scores.
Treatment and cognitive outcomes for MPS IA
A small number of studies have reported cognitive outcomes for children with MPS IA who 
were treated by ERT. Until very recently, no study had tested the hypothesis that earlier 
diagnosis and treatment of MPS IA resulted in fewer brain abnormalities and improved 
cognitive outcomes. These studies of cognitive outcomes among children with MPS IA who 
were treated with ERT are reviewed here and are summarized in Table 2.
Wang and colleagues20 reported outcomes for two siblings who were diagnosed at 
approximately the same time when they were 48 and 3 months of age, and who each started 
ERT 3 months after diagnosis. Although both children were in the normal cognitive range 
(no test scores reported), magnetic resonance imaging (MRI) tests conducted before and 
after 48 months of treatment showed extensive white matter abnormalities in the older 
sibling that diminished with treatment, but the young sibling had few abnormalities at either 
point in time.
Valayannopoulos and colleagues21 reported both cognitive and MRI outcomes for three 
unrelated children (Patients 1, 2, and 3) who had late initiation of ERT following diagnosis 
at ages 42, 72, and 120 months of age. All three had full-scale IQ test scores in the normal 
range at baseline, but the two children diagnosed at younger ages had significant 
improvements over 30–36 months of treatment, with IQ gains of 13 and 29 points. Gains in 
the verbal and nonverbal domains were evident. Patient 2 had significant academic problems 
that resolved following treatment. MRI scans of patients 2 and 3 showed significant 
improvements in white matter involvement, whereas patient 1 had no significant 
abnormalities at baseline.
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Another study by Shapiro and colleagues22 reported cognitive outcomes for seven children 
with MPS IA tested at a mean age of 16 years who had been administered ERT for a 
maximum of 6 years. The mean cognitive score was 85 (low average). The authors 
concluded that the below-average mean IQ in the MPS IA group “dispels any notion that 
their CNS is entirely intact.” Moreover, the authors suggested that the cognitive limitations 
seen in MPS IA patients may warrant educational and vocational modifications.
A more recent study8 reported more extensive cross-sectional data for 21 patients with MPS 
IA who were 72 months or older (mean age, 15.5 years) as well as 4 patients with MPS IA 
younger than 72 months (mean age, 4.3 years) at the time of evaluation. Mean full-scale IQ 
scores were 91 and 109, respectively, and the percentages with full-scale IQ in the average 
range were 57% and 100%, respectively. There was an 18-point difference in verbal IQ 
between MPS IA children who were assessed at younger ages (≤72 months) compared with 
those assessed at older ages (>72 months), with the younger children performing more than 
1 standard deviation better than those assessed at later ages. Similarly, there was a 13-point 
difference in nonverbal IQ between these two groups, with the younger children with MPS 
IA performing better than those with MPS IA detected later. The predominant predictor of 
IQ score was genotype, and having one severe mutation was associated with a 20-point 
lower IQ score. Almost 30% of the patients 72 months of age and older had a severe 
mutation compared with none of the younger patients. In a regression equation that 
controlled for genotype and somatic symptoms, age at initiation of treatment had a modest 
effect that was not significant at the 0.05 level, with each 12-month delay in initiation of 
treatment associated with a 2-point lower IQ score.
The influence of genotype on MPS IA outcomes has been reported elsewhere. One study23 
identified a subset of individuals with MPS IA who were at risk for both psychiatric 
problems and cognitive impairment, specifically those carrying an L238Q missense 
mutation. In a sample of 14 patients with MPS IA who were ages 15–25 years, the mean IQ 
score for six L238Q carriers was 74 (below average) compared with 95 (average) for non-
L238Q carriers (P = 0.016). These results support those of Shapiro and colleagues and 
suggest that genotype may be an important consideration when considering developmental 
trajectory among patients with MPS I.
Al-Sannaa and colleagues24 used a sample of 20 patients with MPS IA from nine affected 
sibships in seven countries to assess the impact of treatment on younger siblings before 
disease manifestation. Younger siblings were stratified by age at ERT initiation to gain 
further insight into the influence of early diagnosis and treatment. Symptoms were absent or 
mild for younger siblings who started ERT at age 12 months or younger. Younger siblings 
who started ERT between ages 24 and 48 months had more motor and cognitive deficits and 
more restriction in activities of daily living than the younger siblings who started ERT 
earlier in life (≤12 months). Younger siblings who started ERT at age younger than 12 
months had fewer motor and cognitive deficits than their older siblings. In summary, these 
results suggest that ERT treatment before disease manifestation can attenuate cognitive 
declines, especially among children who initiate treatment in the first few years of life.
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DISCUSSION
The Advisory Committee recommended that MPS I be added to the RUSP because of the 
potential cognitive benefit of early identification through newborn screening. Cognitive 
scores decrease with increasing age among untreated children with MPS IH, and this review 
supports the hypothesis that earlier age of treatment is associated with significantly 
improved cognitive function. We found studies supporting that HCT at younger than 9 or 16 
months of age was associated with significantly better cognitive outcomes and lower risk of 
cognitive impairment,2,16 and that a 12-month delay in HCT can reduce final IQ scores by 
approximately 8 points after controlling for genotype.8 Overall, early HCT treatment 
prevents further cognitive decline and allows for stabilization and potential growth in 
cognitive skills.2,14,19
Poe et al.,2 along with others using data from the same patient cohorts,25,26 found 
substantially more favorable long-term cognitive outcomes following early HCT than either 
the longitudinal study by Aldenhoven and colleagues16 or the cross-sectional study by 
Shapiro and colleagues.8 The differences in outcomes might be attributable to younger age 
at HCT (2–8 months)2 versus 2–47 months16 or 24–71 months.8 In addition, the differences 
might reflect improvements in treatment over time (HCT between 1997 and 20132 versus 
between 1995 and 200626 and between 1985 and 2011).16 Reports of transplantations 
performed most recently2 used standardized transplant protocols and methods of 
developmental assessment; therefore, they were less heterogeneous than previous studies. 
ERT, whether alone or in combination with HCT, appears to attenuate cognitive decline in 
MPS I. The mechanism of attenuation is unclear because ERT does not cross the blood–
brain barrier.27,28 One prospective study indicates that among children with MPS IH who 
were treated for 12 months with ERT alone, treatment before 18 months was associated with 
less deterioration in cognitive function.19 Another prospective study compared children with 
MPS IH who received either HCT alone or ERT with HCT; the decline in DQ scores during 
24 months of follow-up was much greater for the HCT only group.15
Mild cognitive impairment is common among children with MPS IA,8,22 particularly in 
association with the L238Q missense mutation.8,23 Cognitive outcomes for MPS IA merit 
further attention by researchers. In particular, researchers might investigate the impact of 
verbal versus nonverbal abilities and attention skills on cognitive measures and whether 
earlier initiation of ERT for children with MPS IA associated with the L238Q missense 
mutation leads to less cognitive impairment.
Although language development appears to benefit from earlier treatment2 and can 
normalize over time,18 cognitive and attention skills can remain suboptimal for children 
regardless of the age at HCT.17 Many children with MPS IH require special education 
services even after HCT.8,17 Even after treatment, children with MPS IH typically perform 
worse than those with MPS IA on measures of spatial judgment and attention.22
Intellectual function and academic performance depend on the complex relationship between 
verbal, nonverbal, and attention skills. Although early treatment for MPS IH leads to 
improved cognitive outcomes overall, treatment can still leave important gaps in overall 
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function. Future work is needed to identify other supportive therapies that could target 
specific academic and cognitive domains that are not directly improved with early treatment 
with HCT or ERT.
This review identified significant research gaps related to developmental outcomes in MPS I. 
Additional analyses of existing data that have already been published could yield valuable 
information. For example, it would be useful to test whether there might be a nonlinear 
association of IQ with age at treatment rather than assume a linear regression. Similarly, 
investigators that used a single age cutoff for initiation of treatment could revisit their data to 
determine how use of a different age cutoff might alter results. Finally, it might be helpful to 
stratify data by time period to investigate whether improvements in clinical practice over 
time might have altered the association of age of treatment with cognitive outcomes.
The rarity of MPS I makes it difficult to assess and understand the relationship between age 
at specific treatments and developmental outcomes. The MPS I Disease Registry (https://
www.mps1disease.com/en/patients/mpsi-registry.aspx) could play an important role in 
improving outcomes through better knowledge regarding expected outcomes and the relative 
benefit of different treatment strategies if standardized measures of intellectual function are 
collected at common ages. A registry approach may be especially beneficial to 
understanding the developmental trajectory of and treatment response among the small 
number of identified MPS IA patients. Important considerations for both MPS IH and MPS 
IA include long-term patterns of change over time in verbal, nonverbal, and attention scores 
based on patient diagnosis and specific treatment and the role of other supportive 
interventions.
Conclusion
In summary, consistent evidence from multiple peer-reviewed studies indicates that earlier 
initiation of treatment (ERT and/or HCT) for children with MPS IH is associated with 
markedly better cognitive functioning overall. Transplantation in the first year, preferably as 
early as possible, is a particularly strong predictor of improved cognitive performance and 
continued cognitive growth.2,24 This review did not assess impacts on sub-scale results by 
developmental domain. Future analyses should consider assessments of differential impacts 
of MPS I treatment on verbal versus nonverbal cognitive development, academic skills, and 
attention skills. Also, more work is needed to understand the different cognitive trajectories 
for patients with MPS IA, an understudied patient group.
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